This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Durrheim, D. N. et al. A dangerous measles future looms beyond the COVID-19 pandemic. Nat. Med. 27, 360–361 (2021). https://doi.org/10.1038/s41591-021-01237-5.
Hashiguchi, T. et al. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. Proc. Natl Acad. Sci. USA 115, 2496–2501 (2018).
Tatsuo, H., Ono, N., Tanaka, K. & Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893–897 (2000).
Chang, A. & Dutch, R. E. Paramyxovirus fusion and entry: multiple paths to a common end. Viruses 4, 613–636 (2012).
Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690–698 (2008).
Welsch, J. C. et al. Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J. Virol. 87, 13785–13794 (2013).
Malvoisin, E. & Wild, F. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J. Virol. 64, 5160–5162 (1990).
Fayolle, J., Verrier, B., Buckland, R. & Wild, T. F. Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization. J. Virol. 73, 787–790 (1999).
Avila, M. et al. Molecular determinants defining the triggering range of prefusion F complexes of canine distemper virus. J. Virol. 88, 2951–2966 (2014).
Czuppon, P. et al. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Comput Biol. 17, e1008752 (2021).
Acknowledgements
We thank J. S. Orange and S. G. Kernie for their contributions to this study.
Funding
The work was supported by grants from the NIH: AI121349, NS091263, and NS105699, AI146980 to M.P., from the French ANR NITRODEP (ANR-13-PDOC-0010-01) to C.M. and from the Region Auvergne Rhone Alpes and LABEX ECOFECT (ANR-11-LABX-0048) of Lyon University within the program “Investissements d'Avenir” (ANR-11-IDEX-0007), operated by the French National Research Agency (ANR) to B.H. The Sharon Golub Fund at Columbia University Irving Medical Center (CUIMC).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
C.M., A.M., B.H., and M.P. have submitted a provisional on the use of the scFv.
Rights and permissions
About this article
Cite this article
Mathieu, C., Ferren, M., Harder, O. et al. Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo. Cell Mol Immunol 18, 1835–1837 (2021). https://doi.org/10.1038/s41423-021-00691-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-021-00691-y